Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roquefort Investments PLC ( (GB:ROQ) ) has provided an announcement.
Roquefort Therapeutics has announced the conversion of £80,000 worth of convertible loan notes into 6,282,264 new ordinary shares. This conversion, which includes accrued interest, is part of the company’s financial strategy to manage its capital structure. The new shares will be admitted to trading on the London Stock Exchange, increasing the company’s total issued share capital to 163,726,294 ordinary shares. This move is significant for shareholders as it affects voting rights and shareholding calculations under regulatory rules.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the London Stock Exchange, focusing on acquiring exclusive license rights to innovative drug alternatives for cancer treatment. The company is in the process of completing a transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. to acquire rights to AO-252, a novel drug targeting the TACC3 protein.
Average Trading Volume: 2,523,957
Technical Sentiment Signal: Sell
Current Market Cap: £2.13M
For detailed information about ROQ stock, go to TipRanks’ Stock Analysis page.